Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.

Chung J, Bauer DE, Ghamari A, Nizzi CP, Deck KM, Kingsley PD, Yien YY, Huston NC, Chen C, Schultz IJ, Dalton AJ, Wittig JG, Palis J, Orkin SH, Lodish HF, Eisenstein RS, Cantor AB, Paw BH.

Sci Signal. 2015 Apr 14;8(372):ra34. doi: 10.1126/scisignal.aaa5903.

2.

TMEM14C is required for erythroid mitochondrial heme metabolism.

Yien YY, Robledo RF, Schultz IJ, Takahashi-Makise N, Gwynn B, Bauer DE, Dass A, Yi G, Li L, Hildick-Smith GJ, Cooney JD, Pierce EL, Mohler K, Dailey TA, Miyata N, Kingsley PD, Garone C, Hattangadi SM, Huang H, Chen W, Keenan EM, Shah DI, Schlaeger TM, DiMauro S, Orkin SH, Cantor AB, Palis J, Koehler CM, Lodish HF, Kaplan J, Ward DM, Dailey HA, Phillips JD, Peters LL, Paw BH.

J Clin Invest. 2014 Oct;124(10):4294-304. doi: 10.1172/JCI76979. Epub 2014 Aug 26.

3.

Snx3 regulates recycling of the transferrin receptor and iron assimilation.

Chen C, Garcia-Santos D, Ishikawa Y, Seguin A, Li L, Fegan KH, Hildick-Smith GJ, Shah DI, Cooney JD, Chen W, King MJ, Yien YY, Schultz IJ, Anderson H, Dalton AJ, Freedman ML, Kingsley PD, Palis J, Hattangadi SM, Lodish HF, Ward DM, Kaplan J, Maeda T, Ponka P, Paw BH.

Cell Metab. 2013 Mar 5;17(3):343-52. doi: 10.1016/j.cmet.2013.01.013. Epub 2013 Feb 14.

4.

Correction: A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability.

Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Puijenbroek AAFL, van Noort PI, Prevost GP, Schaapveld RQJ, Cuppen E.

PLoS One. 2013 Jan 22;8(1). doi: 10.1371/annotation/ebea4bd5-2b96-4842-b110-2f7c156e5060. eCollection 2013.

5.

Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts.

Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL, Narla A, Seguin A, Hattangadi SM, Medlock AE, Langer NB, Dailey TA, Hurst SN, Faccenda D, Wiwczar JM, Heggers SK, Vogin G, Chen W, Chen C, Campagna DR, Brugnara C, Zhou Y, Ebert BL, Danial NN, Fleming MD, Ward DM, Campanella M, Dailey HA, Kaplan J, Paw BH.

Nature. 2012 Nov 22;491(7425):608-12. doi: 10.1038/nature11536. Epub 2012 Nov 7. Erratum in: Nature. 2013 Apr 18;496(7445):386.

6.

A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability.

Poell JB, van Haastert RJ, de Gunst T, Schultz IJ, Gommans WM, Verheul M, Cerisoli F, van Puijenbroek AAFL, van Noort PI, Prevost GP, Schaapveld RQ, Cuppen E.

PLoS One. 2012;7(8):e43569. doi: 10.1371/journal.pone.0043569. Epub 2012 Aug 22. Erratum in: PLoS One. 2013 Jan 22;8(1):.

7.

Iron and porphyrin trafficking in heme biogenesis.

Schultz IJ, Chen C, Paw BH, Hamza I.

J Biol Chem. 2010 Aug 27;285(35):26753-9. doi: 10.1074/jbc.R110.119503. Epub 2010 Jun 3. Review.

8.

Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis.

Nilsson R, Schultz IJ, Pierce EL, Soltis KA, Naranuntarat A, Ward DM, Baughman JM, Paradkar PN, Kingsley PD, Culotta VC, Kaplan J, Palis J, Paw BH, Mootha VK.

Cell Metab. 2009 Aug;10(2):119-30. doi: 10.1016/j.cmet.2009.06.012.

9.

Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence.

Schultz IJ, De Kok JB, Witjes JA, Babjuk M, Willems JL, Wester K, Swinkels DW, Tjalsma H.

Anticancer Res. 2007 Mar-Apr;27(2):1051-8.

10.

The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma.

Schultz IJ, Kiemeney LA, Roelofs R, Van Aarssen Y, Babjuk M, Willems JL, Malmström PU, Swinkels DW, Witjes JA, De Kok JB.

Anticancer Res. 2007 Mar-Apr;27(2):1025-30.

11.

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, Malmström PU, de Kok JB.

Eur Urol. 2007 Feb;51(2):416-22; discussion 422-3. Epub 2006 Aug 7.

PMID:
16920253
12.

Survivin and MKI67 mRNA expression in bladder washings of patients with superficial urothelial cell carcinoma correlate with tumor stage and grade but do not predict tumor recurrence.

Schultz IJ, Kiemeney LA, Willems JL, Swinkels DW, Witjes JA, de Kok JB.

Clin Chem. 2006 Jul;52(7):1440-2. No abstract available.

13.

Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study.

Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, de Kok JB, Malmström PU.

Int J Cancer. 2006 Oct 15;119(8):1915-9.

14.

Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin.

Schultz IJ, Witjes JA, Swinkels DW, de Kok JB.

Clin Chim Acta. 2006 Jun;368(1-2):20-32. Epub 2006 Feb 9. Review.

PMID:
16480698
15.

CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas.

Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB.

Int J Cancer. 2005 Aug 20;116(2):282-4.

16.

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, Gunnewiek JM, de Kok JB.

Clin Chem. 2004 Aug;50(8):1425-8. No abstract available.

17.

Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.

Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB.

Anticancer Res. 2003 Jul-Aug;23(4):3327-31.

PMID:
12926071

Supplemental Content

Loading ...
Support Center